U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C26H18N4O2S
Molecular Weight 450.512
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of CCG-63802

SMILES

CC1=CC(OC2=C(\C=C(/C#N)C3=NC4=CC=CC=C4S3)C(=O)N5C=CC=C(C)C5=N2)=CC=C1

InChI

InChIKey=VFSVKVQMZDJFQX-NBVRZTHBSA-N
InChI=1S/C26H18N4O2S/c1-16-7-5-9-19(13-16)32-24-20(26(31)30-12-6-8-17(2)23(30)29-24)14-18(15-27)25-28-21-10-3-4-11-22(21)33-25/h3-14H,1-2H3/b18-14+

HIDE SMILES / InChI

Molecular Formula C26H18N4O2S
Molecular Weight 450.512
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23054060 | https://www.ncbi.nlm.nih.gov/pubmed/26478461

CCG-63802 is a reversible inhibitor of regulator of G-protein signaling (RGS) protein, with the greatest potency at RGS4. Its mechanism seems to, at least in part, involve an allosteric action at the B site on the RGS which has been implicated in the physiological allosteric modulation of RGS proteins by acidic phospholipids and calmodulin. Regulators of G protein signaling (RGS) are major determinants of metabotropic receptor activity, reducing the lifespan of the GTP-bound state of G proteins. Inhibition of spinal RGS4 restored endogenous analgesic signaling pathways and mitigated neuropathic pain. Signalling through CB1 receptors may be involved in this beneficial effect.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
9.0 µM [IC50]
112.0 µM [IC50]
Target ID: P49795
Gene ID: 10287.0
Gene Symbol: RGS19
Target Organism: Homo sapiens (Human)
20.0 µM [IC50]
Target ID: O15492
Gene ID: 6004.0
Gene Symbol: RGS16
Target Organism: Homo sapiens (Human)
42.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Reversible, allosteric small-molecule inhibitors of regulator of G protein signaling proteins.
2010 Sep

Sample Use Guides

Rats were treated with (0.05mg/mL, 10μL intrathecal injection)
Route of Administration: Other
Biotinylated RGS proteins (5 nM, final assay concentration) were immobilized on Luminex LumAvidin beads and incubated with diluted compound in 50 mM HEPES, pH 8.0 at room temperature, 100 mM NaCl, 0.1% Lubrol, and 1 mM DTT, supplemented with 1% BSA. To each well of a 96-well PCR plate (Axygen, Union City, CA) Alexa Fluor 532-labeled G_o was added to a final concentration of 30 nM. This mixture was incubated for 30 min at room temperature in the dark, and then it was analyzed on a Luminex 200 flow cytometer for the bead-associated fluorescence (median value). Nonlinear regression analysis of inhibition curves was performed with Prism 5.0 (GraphPad Software Inc., San Diego CA)
Substance Class Chemical
Created
by admin
on Sat Dec 16 04:51:31 GMT 2023
Edited
by admin
on Sat Dec 16 04:51:31 GMT 2023
Record UNII
339BU4Y35U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CCG-63802
Common Name English
2-BENZOTHIAZOLEACETONITRILE, .ALPHA.-((9-METHYL-2-(3-METHYLPHENOXY)-4-OXO-4H-PYRIDO(1,2-A)PYRIMIDIN-3-YL)METHYLENE)-
Systematic Name English
Code System Code Type Description
EPA CompTox
DTXSID10211064
Created by admin on Sat Dec 16 04:51:31 GMT 2023 , Edited by admin on Sat Dec 16 04:51:31 GMT 2023
PRIMARY
PUBCHEM
6057678
Created by admin on Sat Dec 16 04:51:31 GMT 2023 , Edited by admin on Sat Dec 16 04:51:31 GMT 2023
PRIMARY
CAS
620112-78-9
Created by admin on Sat Dec 16 04:51:31 GMT 2023 , Edited by admin on Sat Dec 16 04:51:31 GMT 2023
PRIMARY
FDA UNII
339BU4Y35U
Created by admin on Sat Dec 16 04:51:31 GMT 2023 , Edited by admin on Sat Dec 16 04:51:31 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY